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Intensity of renal support does 
not affect outcomes in critically ill 
patients with AKI
The delivery of renal-replacement therapy in critically ill patients 
with acute kidney injury (AKI) is controversial with regard to 
dialysis dose, dialysis method, and membrane used. The Veterans 
Administration/National Institutes of Health Acute Renal Failure 
Trial Network study examined two strategies for renal-replacement 
therapy. In the multicenter, prospective, randomized, parallel-
group trial, eligible patients had AKI clinically consistent with 
acute tubular necrosis and requiring renal-replacement therapy, as 
well as sepsis or failure of one or more nonrenal organ systems. All 
subjects received intermittent hemodialysis when they were hemo-
dynamically stable and continuous venovenous hemodiafiltration 
or sustained low-efficiency dialysis when they were hemodynami-
cally unstable. Subjects received either the intensive-therapy or the 
less-intensive-therapy strategy. In the intensive-therapy strategy, 
dialysis was provided in one of the previously described modes 
six times per week. If continuous venous hemodiafiltration was 
provided, it had a flow rate of the total effluent of 35 ml/kg of body 
weight per hour. The less-intensive strategy provided dialysis three 
times per week or had a total-effluent flow rate of 20 ml/kg. The 
goal in both groups was to provide a single-pool Kt/V of between 
1.2 and 1.4 per session.
Outcomes were similar in the two groups. The primary study 
end point, death from any cause at day 60, occurred in 53.6% 
and 51.5% of the intensive-strategy and less-intensive-strategy 
groups, respectively (P = 0.47). No differences were seen between 
groups in the in-hospital death rate, the rate at which subjects 
were discharged to home off-dialysis, recovery of renal function 
by day 28, ICU-free days, or organ failure-free days. 
The authors conclude that intensive renal support in critically ill 
patients with AKI does not decrease mortality, accelerate recovery 
of kidney function, or alter the rate of nonrenal organ failure. Prior 
works suggesting that a threshold for adequacy influences outcomes 
are not obviated by these results. (N Engl J Med advance online 
publication, 20 May 2008, doi:10.1056/NEJMoa0802639)
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Mice lacking angiotensin-
converting enzyme have higher 
energy expenditure, less fat,  
better glucose clearance
In addition to its role in the storage of fat, adipose tissue acts as 
an endocrine organ and contains a functional renin–angiotensin 
system (RAS). Angiotensin-converting enzyme (ACE) plays a key 
role in the RAS by converting angiotensin I to the bioactive peptide 
angiotensin II. Jayasooriya et al. studied the effect of targeting the 
RAS in body energy homeostasis and glucose tolerance by compar-
ing homozygous mice in which the gene for ACE had been deleted 
(ACE–/–) with wild-type littermates. ACE–/– mice had lower body 
weight and a lower proportion of body fat, especially in the abdo-
men. Comparison of axial magnetic resonance images of ACE–/– 
and wild-type mice shows the influence of ACE deficiency on the 
accumulation of android fat, particularly in the visceral region (Fig-
ure). ACE–/– mice had greater fed-state total energy expenditure 
and resting energy expenditure than wild-type littermates. There 
were pronounced increases in gene expression of enzymes related 
to lipolysis and fatty acid oxidation (lipoprotein lipase, carnitine 
palmitoyl transferase, long-chain acetyl coenzyme A dehydroge-
nase) in the livers of ACE–/– mice and also lower plasma leptin. In 
contrast, no differences were detected in daily food intake, activ-
ity, fed-state plasma lipids, or proportion of fat excreted in fecal 
matter. In conclusion, the reduction in ACE activity is associated 
with a decreased accumulation of body fat, especially in abdominal 
fat depots. The decreased body fat in ACE–/– mice is independent 
of food intake and appears to be due to a high energy expendi-
ture related to increased metabolism of fatty acids in the liver and 
glucose tolerance. (Proc Natl Acad Sci USA 2008; 105: 6531–6536; 
doi:10.1073/pnas.0802690105)
Detlef Schlöndorff
Deficiency in catechol-O-
methyltransferase and 
2-methoxyestradiol is  
associated with preeclampsia
Preeclampsia is characterized by placental hypoxia, hypertension, 
proteinuria, and edema. Intensive investigations have not clarified 
the mechanisms that mediate appearance of this syndrome. 
Recent work has suggested that hypoxia-driven disruption of the 
angiogenic balance involving vascular endothelial growth factor 
(VEGF)/placenta-derived growth factor (PLGF) and soluble 
Fms-like tyrosine kinase-1 (sFLT-1, the soluble form of VEGF 
receptor 1) might contribute to some of the maternal symptoms 
of preeclampsia. However, preeclampsia does not develop in all 
women with high sFLT-1 or low PLGF levels, and it also occurs in 
some women with low sFLT-1 and high PLGF levels. Moreover, 
 
 
 
 
  
Wild-type ACE -/-
Proton density-weighted axial magnetic resonance images across the 
body of ACE+/+ and ACE–/– mice. Bright, white areas denote fat. 
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recent experiments strongly suggest that several factors affecting 
the vasculature are probably elevated because of placental hypoxia 
in preeclamptic women, indicating that an upstream molecular 
defect or defects may contribute to the condition. In a recent 
publication, Kanasaki et al. report that pregnant mice deficient in 
catechol-O-methyltransferase (COMT) showed a preeclampsia-
like phenotype resulting from an absence of 2-methoxyestradiol, 
a natural metabolite of estradiol. The blood pressures of Comt–/– 
mice were significantly elevated late in pregnancy but returned 
to normal levels within 10 days after delivery, mimicking a 
similar trend observed in post-delivery preeclamptic women 
(Figure). Importantly, exogenous 2-methoxyestradiol prevented 
an increase in blood pressure in pregnant Comt–/– mice. Also, 
an inhibitor of COMT (Ro41-0960) administered to wild-type 
pregnant mice elevated blood pressure during later stages of 
pregnancy. Proteinuria, another clinical feature of preeclampsia, 
was higher in Comt–/– mice. Wild-type mice treated with the 
inhibitor of COMT also excreted more urinary albumin, and 
administration of 2-methoxyestradiol to pregnant Comt–/– 
mice prevented proteinuria. Electron microscopy revealed 
kidney glomerular endothelial cell detachment, swelling, and 
vacuolization late in pregnancy in Comt–/– mice; these glomerular 
lesions were not observed in pregnant 2-methoxyestradiol-
treated Comt–/– mice. 2-Methoxyestradiol was generated by 
COMT in the placenta and increased in concentration during 
the third trimester of normal human pregnancy. The authors 
also found that the circulating levels of 2-methoxyestradiol 
were lower in female mice with preeclampsia than in normal 
pregnant female mice, and that COMT protein expression 
was significantly lower in the third-trimester preeclamptic 
placentae than in control placentae. Among several actions, 
2-methoxyestradiol inhibits hypoxia-inducible factor-1α 
(HIF-1α), a transcription factor that senses tissue oxygen tension 
and regulates the expression of hypoxia-induced genes. Because 
HIF-1α is induced in placentae of preeclamptic women, it is 
likely that diminished COMT/2-methoxyestradiol levels may 
contribute to the elevation of placental HIF-1α. These studies 
suggest that 2-methoxyestradiol may have utility as a plasma and 
urine diagnostic marker for preeclampsia and could serve as a 
therapeutic agent. (Nature advance online publication, 11 May 
2008, doi:10.1038/nature06951)
Juan Oliver
Hypertension resulting from a 
defect in vascular function
Genetic studies of patients with early-onset hypertension or 
hypotension inherited in the classic mendelian manner have 
identified abnormalities in renal sodium handling, suggesting that 
hypertension arises exclusively from impaired renal salt excretion 
and extracellular volume expansion. Acute changes in vascular tone 
can increase vascular resistance and blood pressure, but whether 
primary abnormalities of vascular smooth muscle tone can cause 
hypertension remains unclear. Increases in intracellular calcium 
in vascular smooth muscle cells activate myosin light chain kinase, 
which phosphorylates myosin light chains, activating myosin 
ATPase and increasing muscle cell contraction and vascular 
tone. Conversely, activation of myosin light chain phosphatase 
dephosphorylates myosin light chains and causes vascular smooth 
muscle relaxation. The relative proportion of phosphorylated and 
dephosphorylated myosin light chains thus determines the state 
of vascular tone. Nitric oxide, the most important endogenous 
vasodilator, causes smooth muscle cell relaxation by increasing 
cGMP and activating cGMP-dependent protein kinases (PKGI). 
Mice with deletion of the PKGI gene die shortly after birth, 
precluding detailed investigation of their cardiovascular function. 
This gene encodes two isoforms; one, PKGIα is expressed in vascular 
smooth muscle cells, where it binds and activates myosin light chain 
phosphatase, causing myosin light chain dephosphorylation and 
relaxation. Michael et al. now report the generation of knock-in 
mice harboring a discrete mutation in PKGIα, that disrupts the 
domain essential for PKGIα-mediated regulation of vascular 
smooth muscle myosin phosphatase. These LZM mice had 
sustained elevations of blood pressure that were independent of 
the salt intake (Figure). Importantly, glomerular filtration rate, renal 
plasma flow, and plasma aldosterone were no different between 
the control and LZM mice, making it unlikely that changes in 
renal function caused hypertension. Although subtle changes in 
extracellular fluid volume are notoriously difficult to detect, these 
experiments suggest that high blood pressure can arise from a 
primary abnormality of vascular smooth muscle function. This 
opens the door for new approaches to the diagnosis and therapy of 
a broad range of blood pressure disorders. (Proc Natl Acad Sci USA 
2008; 105: 6702–6707; doi:10.1073/pnas.0802128105)
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Systolic blood pressure in nonpregnant mice and pregnant mice on days 
10 and 17 of gestation and 10 days after delivery.
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Blood pressure in wild-type (WT) and LZM mice on normal-salt and 
altered-salt diets. LZM mice have significant increases in blood pressure 
compared with wild-type mice.
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